Advances in anemia management in chronic kidney disease

Joanna Laizure, Kristine S. Schonder

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

The prevalence of chronic kidney disease (CKD) is increasing in the United States. Efforts to promote earlier intervention to screen for CKD and manage secondary complications are of paramount importance to improve overall care of this population. Anemia is a secondary complication of CKD that develops as kidney function declines. Historically, anemia management efforts have been primarily emphasized in patients with end-stage renal disease; however, early detection and treatment of anemia in the early stages of the disease are essential to prevent negative consequences of anemia such as reduced quality of life, left ventricular hypertrophy and mortality. With the increased prevalence of CKD and efforts focused on identifying this disorder early in its course, it is likely that more pharmacists will be involved in the management of CKD and secondary complications such as anemia. Treatment approaches must also be based on the more recently advocated guidelines from the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (NKF-K/ DOQI). This article reviews therapeutic issues of anemia of CKD, new agents for management, and the NKF-K/DOQI anemia management guidelines from a clinical perspective that will assist pharmacists involved in the care of these patients.

Original languageEnglish (US)
Pages (from-to)437-455
Number of pages19
JournalJournal of Pharmacy Practice
Volume15
Issue number6
DOIs
StatePublished - Dec 1 2002

Fingerprint

Chronic Renal Insufficiency
Anemia
Pharmacists
Guidelines
Kidney
Kidney Diseases
Left Ventricular Hypertrophy
Chronic Kidney Failure
Patient Care
Therapeutics
Quality of Life
Mortality
Population

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Advances in anemia management in chronic kidney disease. / Laizure, Joanna; Schonder, Kristine S.

In: Journal of Pharmacy Practice, Vol. 15, No. 6, 01.12.2002, p. 437-455.

Research output: Contribution to journalReview article

Laizure, Joanna ; Schonder, Kristine S. / Advances in anemia management in chronic kidney disease. In: Journal of Pharmacy Practice. 2002 ; Vol. 15, No. 6. pp. 437-455.
@article{ba24463b071d4b13b27e39d7fe95c804,
title = "Advances in anemia management in chronic kidney disease",
abstract = "The prevalence of chronic kidney disease (CKD) is increasing in the United States. Efforts to promote earlier intervention to screen for CKD and manage secondary complications are of paramount importance to improve overall care of this population. Anemia is a secondary complication of CKD that develops as kidney function declines. Historically, anemia management efforts have been primarily emphasized in patients with end-stage renal disease; however, early detection and treatment of anemia in the early stages of the disease are essential to prevent negative consequences of anemia such as reduced quality of life, left ventricular hypertrophy and mortality. With the increased prevalence of CKD and efforts focused on identifying this disorder early in its course, it is likely that more pharmacists will be involved in the management of CKD and secondary complications such as anemia. Treatment approaches must also be based on the more recently advocated guidelines from the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (NKF-K/ DOQI). This article reviews therapeutic issues of anemia of CKD, new agents for management, and the NKF-K/DOQI anemia management guidelines from a clinical perspective that will assist pharmacists involved in the care of these patients.",
author = "Joanna Laizure and Schonder, {Kristine S.}",
year = "2002",
month = "12",
day = "1",
doi = "10.1177/089719002237664",
language = "English (US)",
volume = "15",
pages = "437--455",
journal = "Journal of Pharmacy Practice",
issn = "0897-1900",
publisher = "SAGE Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Advances in anemia management in chronic kidney disease

AU - Laizure, Joanna

AU - Schonder, Kristine S.

PY - 2002/12/1

Y1 - 2002/12/1

N2 - The prevalence of chronic kidney disease (CKD) is increasing in the United States. Efforts to promote earlier intervention to screen for CKD and manage secondary complications are of paramount importance to improve overall care of this population. Anemia is a secondary complication of CKD that develops as kidney function declines. Historically, anemia management efforts have been primarily emphasized in patients with end-stage renal disease; however, early detection and treatment of anemia in the early stages of the disease are essential to prevent negative consequences of anemia such as reduced quality of life, left ventricular hypertrophy and mortality. With the increased prevalence of CKD and efforts focused on identifying this disorder early in its course, it is likely that more pharmacists will be involved in the management of CKD and secondary complications such as anemia. Treatment approaches must also be based on the more recently advocated guidelines from the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (NKF-K/ DOQI). This article reviews therapeutic issues of anemia of CKD, new agents for management, and the NKF-K/DOQI anemia management guidelines from a clinical perspective that will assist pharmacists involved in the care of these patients.

AB - The prevalence of chronic kidney disease (CKD) is increasing in the United States. Efforts to promote earlier intervention to screen for CKD and manage secondary complications are of paramount importance to improve overall care of this population. Anemia is a secondary complication of CKD that develops as kidney function declines. Historically, anemia management efforts have been primarily emphasized in patients with end-stage renal disease; however, early detection and treatment of anemia in the early stages of the disease are essential to prevent negative consequences of anemia such as reduced quality of life, left ventricular hypertrophy and mortality. With the increased prevalence of CKD and efforts focused on identifying this disorder early in its course, it is likely that more pharmacists will be involved in the management of CKD and secondary complications such as anemia. Treatment approaches must also be based on the more recently advocated guidelines from the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (NKF-K/ DOQI). This article reviews therapeutic issues of anemia of CKD, new agents for management, and the NKF-K/DOQI anemia management guidelines from a clinical perspective that will assist pharmacists involved in the care of these patients.

UR - http://www.scopus.com/inward/record.url?scp=0036897013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036897013&partnerID=8YFLogxK

U2 - 10.1177/089719002237664

DO - 10.1177/089719002237664

M3 - Review article

VL - 15

SP - 437

EP - 455

JO - Journal of Pharmacy Practice

JF - Journal of Pharmacy Practice

SN - 0897-1900

IS - 6

ER -